From the Department of Ophthalmology (N.A.P., S.H., J.D.) Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts; Bascom Palmer Eye Institute (N.A.P., H.A-K., K.C.F., N.A.Y., A.M.B.) University of Miami Leonard M. Miller School of Medicine, Miami, Florida; Department of Ophthalmology (N.A.P.), Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
From the Department of Ophthalmology (N.A.P., S.H., J.D.) Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts.
Am J Ophthalmol. 2023 Aug;252:147-152. doi: 10.1016/j.ajo.2023.03.007. Epub 2023 Mar 17.
To assess the rates of retinopathy of prematurity (ROP) and treatment-warranted ROP in a modern set of patients meeting 0 or 1 of the current ROP screening criteria.
Retrospective cohort study.
Single-center study of 9350 infants screened for ROP from 2009 to 2019. Rates of ROP and treatment-warranted ROP were evaluated in group 1 (birth weight [BW] <1500 g and gestational age [GA] ≥30 weeks), group 2 (BW ≥1500 g and GA <30 weeks), and group 3 (BW ≥1500 g and GA ≥30 weeks).
Of 7520 patients with reported BW and GA, 1612 (21.4%) patients met the inclusion criteria. The number of patients in groups 1, 2, and 3 was 466 (6.19%), 23 (0.31%), and 1123 (14.93%), respectively. The number of patients diagnosed with ROP was 20 (4.29%) in group 1, 1 (4.35%) in group 2, and 12 (1.07%) in group 3 (P < .001). The mean interval between birth and ROP diagnosis was 36.25 days (range 12-75 days) in group 1, 47 days in group 2, and 23.33 days (range 10-39 days) in group 3 (P = .05). No cases of stage 3, zone 1, or plus disease were recorded. No patients met the treatment criteria.
Patients meeting 1 screening criterion had a low rate of ROP (<5%), with no stage 3, zone 1, or plus disease. No patients required treatment. We propose a possible algorithm (TWO-ROP) in appropriate neonatal intensive care units, with an amendment in screening protocol for this low-risk population to include only an outpatient screening examination within 1 week of discharge, or at 40 weeks if inpatient, to decrease the inpatient ROP screening burden while maintaining safety. Further external validation of this protocol would be required.
评估符合现行 ROP 筛查标准 0 或 1 项的现代患者组中早产儿视网膜病变(ROP)和治疗性 ROP 的发生率。
回顾性队列研究。
对 2009 年至 2019 年筛查 ROP 的 9350 名婴儿进行单中心研究。在第 1 组(出生体重[BW] <1500g 且胎龄[GA]≥30 周)、第 2 组(BW≥1500g 且 GA <30 周)和第 3 组(BW≥1500g 且 GA≥30 周)中评估 ROP 和治疗性 ROP 的发生率。
在报告 BW 和 GA 的 7520 名患者中,有 1612 名(21.4%)患者符合纳入标准。第 1、2 和 3 组的患者人数分别为 466(6.19%)、23(0.31%)和 1123(14.93%)。第 1 组诊断为 ROP 的患者有 20 名(4.29%),第 2 组 1 名(4.35%),第 3 组 12 名(1.07%)(P<.001)。第 1 组从出生到 ROP 诊断的平均间隔为 36.25 天(范围 12-75 天),第 2 组为 47 天,第 3 组为 23.33 天(范围 10-39 天)(P=.05)。未记录到 3 期、1 区或加病。没有患者符合治疗标准。
符合 1 项筛查标准的患者 ROP 发生率较低(<5%),无 3 期、1 区或加病。无需治疗。我们提出了一种可能的算法(TWO-ROP),适用于适当的新生儿重症监护病房,对该低危人群的筛查方案进行修正,仅包括出院后 1 周内或住院时 40 周时的门诊筛查检查,以减少住院 ROP 筛查负担,同时保持安全性。还需要对该方案进行进一步的外部验证。